|
Verona Pharma Plc - Company Profile Snapshot
| Company Profile: |
Verona Pharma Plc |
| Ticker: |
VRP |
| Exchanges: |
LON |
| 2008 Sales: |
n/a |
| Major Industry: |
Drugs, Cosmetics & Health Care |
| Sub Industry: |
Ethical Drug Manufacturers |
| Country: |
UNITED KINGDOM |
| Employees: |
5 |
Business Description
Verona Pharma Plc. The Group's principal activity is researching and developing drugs for the treatment of allergic rhinitis and other chronic respiratory diseases such as asthma and chronic obstructive pulmonary disease as well as chronic inflammatory diseases. The Group's lead drug compound, RPL554, is a long acting inhibitor of both phosphodiesterase 3 and phosphodiesterase 4 enzymes, two enzymes known to be of importance in the development and progression of immunological respiratory diseases, particularly rhinitis (hay fever) and asthma.
|
Not the Report you are looking for?
Click here for more browsing options.
|
The following information is available to subscribers or can be accessed by purchasing the Company Profile Report:
|
- Address (mailing), Phone Number, Web Address
- Earnings/Dividends
- Employees
- Exchanges Listed
- Financial Ratio Analysis |
- Recent Stock Performance
- Sales (recent year)
- Senior Officers
- Shareholder Information
- Stock Analysis Summary |
Layout and Content of a Typical Report
|
|
|
|
|
